David Burke

TL;DR: Evidence for plasticity in motoneuronal properties at a molecular level is provided, the first such evidence for intact human subjects, in patients with multiple sclerosis and normal subjects.

TL;DR: It is suggested that the hypo‐excitability produced by brief trains of impulses may be sufficient to disturb conduction in diseased nerve fibers, and that the lesser expression of slow K+ conductances on cutaneous afferents in the sural nerve could render them more sensitive to depolarizing stresses than median afferentS.

TL;DR: The findings indicate that the majority of isolated single afferents and, indeed, the majority-of-afferents within the relevant fascicle are capable of transmitting impulses across the recording site, even though conduction across the impaled internode is slow.

TL;DR: The post‐ischaemic increase in supernormality and the lack of change with changes in axonal excitability can be explained by blockage of voltage‐dependent potassium channels.

TL;DR: Riluzole is the only therapy proven in clinical trials to prolong survival in patients with motor neurone disease (MND). Prior to its listing by the Australian Pharmaceutical Benefits Advisory Scheme in June 2003, the aim of the present study was to provide Australian patients with MND early access to riluzoles and to expand the safety profile data of this therapy.